# Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

> **NCT05925127** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novavax** · enrollment: 994 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** NVX-CoV2373 (5μg)
- **BIOLOGICAL:** NVX-CoV2601 (5μg)
- **BIOLOGICAL:** NVX-CoV2601(5μg)
- **BIOLOGICAL:** NVX-CoV2601 (35μg)
- **BIOLOGICAL:** NVX-CoV2601(35μg)
- **BIOLOGICAL:** NVX-CoV2601(50μg)
- **BIOLOGICAL:** Bivalent BA.4/5

## Key facts

- **NCT ID:** NCT05925127
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-16
- **Primary completion:** 2024-05-21
- **Final completion:** 2024-05-21
- **Target enrollment:** 994 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05925127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05925127, "Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05925127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*